S Umemura, H Arima, S Arima, K Asayama… - Hypertension …, 2019 - nature.com
The Japanese Society of Hypertension (JSH) revised the Guidelines for the Management of Hypertension 2014 (JSH 2014), and published the JSH 2019. In the development of the JSH …
M Azizi, K Sanghvi, M Saxena, P Gosse, JP Reilly… - The Lancet, 2021 - thelancet.com
Background Endovascular renal denervation reduces blood pressure in patients with mild-to- moderate hypertension, but its efficacy in patients with true resistant hypertension has not …
M Böhm, K Kario, DE Kandzari, F Mahfoud, MA Weber… - The Lancet, 2020 - thelancet.com
Background Catheter-based renal denervation has significantly reduced blood pressure in previous studies. Following a positive pilot trial, the SPYRAL HTN-OFF MED (SPYRAL …
S Brouwers, I Sudano, Y Kokubo, EM Sulaica - The Lancet, 2021 - thelancet.com
Arterial hypertension is the most important contributor to the global burden of disease; however, disease control remains poor. Although the diagnosis of hypertension is still based …
M Burnier, BM Egan - Circulation research, 2019 - Am Heart Assoc
The global epidemic of hypertension is largely uncontrolled and hypertension remains the leading cause of noncommunicable disease deaths worldwide. Suboptimal adherence …
Resistant hypertension (RH) is defined as above-goal elevated blood pressure (BP) in a patient despite the concurrent use of 3 antihypertensive drug classes, commonly including a …
DL Bhatt, M Vaduganathan, DE Kandzari, MB Leon… - The Lancet, 2022 - thelancet.com
Summary Background The SYMPLICITY HTN-3 (Renal Denervation in Patients With Uncontrolled Hypertension) trial showed the safety but not efficacy of the Symplicity system …